• 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2021-03
  • 2020-08
  • 2020-07
  • 2020-03
  • 2019-11
  • 2019-10
  • 2019-09
  • 2019-08
  • 2019-07
  • br Support for work br Oonagh Griffin is a recipient


    Support for work
    Oonagh Griffin 3X FLAG Peptide a recipient of a training fellowship from Health Research Board, Ireland (HPF -2015-977)
    We would like to thank Dr Carla Prado, Dr Jingjie Xiao, and Taiwo Olobatuyi at the University of Alberta, Edmonton, Canada for sharing their time, training and expertise in CT-based body composition analysis techniques.
    Appendix A. Supplementary data
    [1] Carrato A, Falcone A, Ducreux M, Valle JW, Parnaby A, Djazouli K, et al. A systematic review of the burden of pancreatic cancer in Europe: real-world impact on survival, quality of life and costs. J Gastrointest Cancer 2015;46(3): 201e11.
    [2] Siegal RL, Miller KD, Jemal A. Cancer Statistics, 2018. CA A Cancer J. Clin. 2018;68(1):7e30. [3] Tempero MA, Malafa MP, Al-Hawary M, Asbun H, Bain A, Behrman SW, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw 2017;15(8):1028e61. [4] Gilliland TM, Villafane-Ferriol N, Shah KP, Shah RM, Tran Cao HS, Massarweh NN, et al. Nutritional and metabolic derangements in pancreatic cancer and pancreatic resection. Nutrients 2017;9(3). [5] Bachmann J, Heiligensetzer M, Krakowski-Roosen H, Buchler MW, Friess H, Martignoni ME. Cachexia worsens prognosis in patients with resectable pancreatic cancer. J Gastrointest Surg 2008;12(7):1193e201.
    [6] Tan BH, Birdsell LA, Martin L, Baracos VE, Fearon KC. Sarcopenia in an over-weight or obese patient is an adverse prognostic factor in pancreatic cancer. Clin Cancer Res 2009;15(22):6973e9.
    [7] Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9(7):629e35.
    [8] Martin L, Birdsell L, Macdonald N, Reiman T, Clandinin MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31(12): 1539e47.
    [9] Ozola Zalite I, Zykus R, Francisco Gonzalez M, Saygili F, Pukitis A, Gaujoux S, et al. Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systematic review. Pancreatology 2015;15(1):19e24. [10] Levolger S, van Vugt JL, de Bruin RW, JN IJ. Systematic review of sarcopenia in patients operated on for gastrointestinal and hepatopancreatobiliary malig-nancies. Br J Surg 2015;102(12):1448e58.
    [11] Fearon K, Strasser F, Anker SD, Bosaeus I, Bruera E, Fainsinger RL, et al. Defi-nition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12(5):489e95. [12] Mourtzakis M, Prado CM, Lieffers JR, Reiman T, McCargar LJ, Baracos VE.
    Please cite this article as: Griffin OM et al., Characterising the impact of body composition change during neoadjuvant chemotherapy for pancreatic cancer, Pancreatology,
    A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. Appl Physiol Nutr Metabol 2008;33(5):997e1006.
    [14] Di Sebastiano KM, Yang L, Zbuk K, Wong RK, Chow T, Koff D, et al. Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anaemia. Br J Nutr 2013;109(2): 302e12.
    [16] Akahori T, Sho M, Kinoshita S, Nagai M, Nishiwada S, Tanaka T, et al. Prog-nostic significance of muscle attenuation in pancreatic cancer patients treated with neoadjuvant chemoradiotherapy. World J Surg 2015;39(12):2975e82.